Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease

Modified monoclonal class-G immunoglobulins (IgG) have been shown to protect infants from respiratory syncytial virus (RSV), a prevalent disease with particularly high morbidity in newborns. We sought to determine whether a clinically relevant monoclonal IgG against RSV could be delivered to the fetus via transammiotic fetal immunotherapy (TRAFIT) and remain bioavailable after birth.